Lung Cancer Clinical Trial
Specialized Radiation Therapy in Treating Patients With Stage II, Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer and Poor Performance Status
Summary
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
PURPOSE: This phase I trial is studying the side effects and best dose of specialized radiation therapy in treating patients with stage II, stage III, stage IV, or recurrent non-small cell lung cancer and poor performance status.
Full Description
OBJECTIVES:
Primary
To escalate the dose of accelerated hypofractionated image-guided conformal radiotherapy to a potent tumoricidal dose without exceeding the maximum-tolerated dose in patients with recurrent or stage II-IV non-small cell lung cancer and poor performance status.
Secondary
To evaluate local regional tumor control and overall survival of patients treated with this regimen.
OUTLINE: Patients undergo accelerated hypofractionated image-guided conformal radiotherapy once daily, 5 days a week, for 3 weeks (15 fractions). Treatment continues in the absence of disease progression or unacceptable toxicity.
After completion of study therapy, patients are followed up periodically for up to 5 years.
Eligibility Criteria
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed non-small cell lung cancer
Stage II-IV and/or recurrent disease
No small cell histology
Measurable or evaluable disease
Tumor not amenable to surgical resection
Tumor not eligible for stereotactic body radiation therapy
No prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
PATIENT CHARACTERISTICS:
Zubrod performance status 2-4
Not pregnant or nursing
Negative pregnancy test
Fertile patients must agree to use effective contraception
Must complete all required pretreatment evaluations
PRIOR CONCURRENT THERAPY:
See Disease Characteristics
More than 1 week since prior chemotherapy or chemoradiation therapy
No concurrent chemotherapy
No other concurrent antineoplastic therapy (including standard-fractionated radiotherapy to the chest, chemotherapy, biological therapy, vaccine therapy, and surgery) 1 week before, during, and for 1 week after completion of study therapy
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 2 Locations for this study
Stanford California, 94305, United States
Dallas Texas, 75390, United States
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.